热门资讯> 正文

Corbus Pharmaceuticals股价下跌17%，每股13美元，股价为7500万美元

2025-10-31 18:10

Corbus制药控股(CRBP) 0

Corbus Pharmaceuticals (CRBP) priced an underwritten public offering of ~4.74M shares at $13.00 per share and pre-funded warrants to purchase ~1.03M shares, for a total public offering size of ~$75M.
The underwriters a 30-day option to purchase up to an additional 865,384 shares of its common stock on the same terms and conditions.
The offering is expected to close on or about November 3, 2025.
Corbus intends to use the net proceeds of the offering to fund the clinical development of its pipeline and for working capital and other general corporate purposes.
The stock price dropped ~17% on Friday during pre-market hours of trading.

More on Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel Transcript
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel - Slideshow
Corbus Pharmaceuticals announces proposed public offering to fund clinical pipeline
Corbus higher as FDA issues another fast track tag for lead asset
Seeking Alpha’s Quant Rating on Corbus Pharmaceuticals

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。